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Patients with carcinoma of the anal canal may be treated with 
combination of radiation and chemotherapy to avoid the need for 
surgical resection of the anus and a permanent colostomy.
The disease is rare and accounts for approximately 1.8% of cancers 
of the gastrointestinal system in the USA.¹ It comprises 4% of the total 
number of cancers of the gastrointestinal tract seen at Groote Schuur 
Hospital (GSH). Aetiological factors include human papillomavirus 
(HPV) infections, particularly type 16, immunosuppression, chronic 
inflammation and smoking.
The tumour arises in the anal transition zone and the majority 
are squamous carcinomas. Only 5 - 10% of patients present with 
metastatic disease. Before the 1970s - 1980s this disease was treated 
surgically with abdominoperineal resection (APR) resulting in a 
permanent colostomy. Recurrence rates were about 40% and the 
majority of relapses were locoregional.² In 1984 the results on 
over 100 patients treated with chemoradiation were published by 
Nigro.3 There was a complete pathological response rate of 93%. 
Results of subsequent trials have led to the recommendation that 
standard treatment for carcinoma of the anal canal is radiation to 
a dose of 45 - 50 Gy with a combination of 5 fluorouracil (5FU) 
and mitomycin C chemotherapy.4-8 APR is generally reserved for 
salvage treatment. Local excision may be considered for tumour 
stage 1 (T1) lesions.
The aim of this paper was to review the characteristics of patients 
presenting with anal canal carcinoma at GSH. We also reviewed the 
treatment and compared our local control, colostomy-free and overall 
survival rates for chemoradiation with those in the literature.
Patients and methods
Patients and staging
The records for all patients presenting with carcinoma of the anal canal 
between January 2000 and December 2004 were reviewed. The age, 
gender, race, stage and HIV status were recorded. Staging investigations 
included chest X-ray and ultrasound or computed tomography (CT) scan 
of the abdomen. Full blood count and serum chemistry were requested. 
Patients were staged according to the 1985 Union for International 
Cancer Control (UICC) classification. All patients were reviewed at a 
multidisciplinary team meeting for a management decision.
Treatment
For patients treated with chemoradiation, the radiation dose was 
either 42.00 Gy in 20 fractions or 44.20 Gy in 20 fractions (after June 
2003) to a central dose, 4 fractions weekly using 60-Cobalt. Anterior 
and posterior fields to the pelvis were based on bony landmarks as 
well as tumour extent. The superior border of the radiation field was 
placed at the lower border of the sacro-iliac joint or the upper border 
of the acetabulum. The inferior border was placed 2 cm below the anal 
verge or 2 cm below visible tumour if the tumour protruded from the 
anal canal. For patients with no inguinal node involvement the lateral 
border was 1 cm lateral to the widest brim of the pelvic side walls. In 
patients with involved inguinal nodes the lateral border was placed 2 
cm lateral to the palpable nodes. Patients without stomas were treated 
prone. The chemotherapy regimen was mitomycin C 12 mg/m² on day 
1 and 5FU 1 000 mg/m² continuous infusion on days 1 - 4, i.e. with the 
first 4 fractions, and 5FU 1 000 mg/m² with the last 4 fractions.
All patients were reviewed 6 weeks after completing treatment. If the 
size of the primary tumour had decreased by more than 50% a further 
dose of 15.00 Gy in 6 fractions was given to the perineum. Patients with 
less than 50% response proceeded to surgery. The response to treatment 
for patients receiving chemoradiation was assessed clinically at the 
completion of treatment. Overall survival, local control and colostomy-
free survival were calculated using the Kaplan-Meier method. The 
ethical conduct of the study was acknowledged by the University of Cape 
Town Faculty of Health Sciences Research Ethics Committee.
Results
Patient characteristics
Thirty-one patients were included in the analysis. Table 1 illustrates 
the patient and tumour characteristics. The median age was 56 years 
(range 18 - 87). There were 15 female patients and 16 male patients. Of 
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Objectives. Chemoradiation is the treatment of choice for squamous 
carcinoma of the anal canal, resulting in the same local control rates 
as surgery but with the advantage of organ function preservation. 
We aimed to review all cases of anal canal carcinoma treated at 
Groote Schuur Hospital between 2000 and 2004 and to assess 
treatment outcome.
Methods. The records for 31 patients presenting during this period 
were reviewed. Patient and tumour characteristics were recorded. 
Twenty-six patients were treated with chemoradiation. Local failure-
free, colostomy-free and overall survival were calculated using the 
Kaplan-Meier method.
Results. Compared with the literature, the median patient age 
was younger and the stage was more advanced in this study. The 
complete response rate for all stages with chemoradiation was 80%. 
The local failure-free survival at 5 years was 60.7%. Colostomy-free 
and overall survival at 5 years were 59.2% and 65.6%, respectively.
Conclusions. The patients presented with locally advanced disease. 
Chemoradiation is effective treatment for this group of patients and 
the majority avoid a permanent colostomy as they preserve anal 
sphincter function.
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22 tested patients only 1 was positive for the human immunodeficiency 
virus (HIV). Locally advanced disease (T3, 4 tumours) was present 
in 67% of patients and 38% had palpable inguinal nodes. Metastatic 
disease was present in 1 patient. Only 1 patient had an adenocarcinoma; 
the remainder were squamous carcinomas.
Treatment
Table 2 shows the treatment summary. Chemoradiation was the 
primary treatment administered to 26 of the 31 patients. Of the 
remaining 5 patients, 2 underwent an APR as their primary treatment 
as they were not suitable for chemoradiation and 3 patients received 
no treatment (poor performance status in 2 and 1 failure to attend). 
A colostomy for obstructive symptoms or faecal incontinence was 
required in 23% (6 patients) prior to chemoradiation.
There was a less than 50% response at initial assessment after 
chemoradiation for 6 of the 26 patients. An APR was undertaken 
on 2 of these patients. Two patients were found to have no 
evidence of residual disease at the time of planned surgery and 
were followed up. Two patients did not receive further treatment 
after chemoradiation because of extensive disease not suitable for 
radiation boost or resection.
Toxicity
Treatment was not completed in 7% (2 patients) because of toxicity. 
Treatment interruptions for grade 2 or 3 toxicity were required 
in 38% (10 patients). The most common toxicity was radiation 
dermatitis. Details of toxicity are shown in Table 3. Treatment was 
interrupted until resolution to grade 1 toxicity.
Late toxicity was observed in 2 patients treated with chemoradiation. 
One required a loop colostomy 3 years after completing treatment for 
anal stenosis causing faecal incontinence and 1 required an APR 2 
years after chemoradiation for persistent anal pain. There was no 
histological evidence of recurrence.
Treatment outcome
The median follow-up time was 49 months. An initial local complete 
response to chemoradiation occurred in 80% of patients (21 of 26). 
There were relapses in 27% (7 patients). Details of treatment outcome 
are shown in Table 4. Only 1 patient with local relapse was suitable for 
APR and remains clear.
The Kaplan-Meier method was used to calculate the local failure-
free, colostomy-free and overall survival rates for patients treated 
with chemoradiation. Local failure was defined as those patients not 
achieving a complete response to chemoradiation and those who 
relapsed locally. Our local failure-free survival at 5 years was 60.7%. 
The colostomy-free survival was 59.2% at 5 years and the 5-year 
overall survival was 65.6%.
Discussion
The majority of articles on squamous carcinoma of the anal canal 
have been published in North America and Europe. Madden et al. 9 
published a retrospective review in 1981 on patients treated at GSH. 
Chemoradiation was not standard care at this time. A further paper 
discussing salvage surgery following chemoradiation was published 
in 1989 from the same institution.10
Table 1. Patient and tumour characteristics
Characteristic N (%)
Sex
Male 16 (52)
Female 15 (48)
Age (years)
Median (range) 56 (18 - 87)
Tumour stage
T1 1 (3)
T2 10 (32)
T3 17 (55)
T4 3 (10)
Node stage
Inguinal nodes not involved 19 (62)
Involved inguinal nodes 12 (38)
Metastatic stage
M0 30 (97)
M1 1 (3)
Histology
Squamous carcinoma 30 (97)
Adenocarcinoma 1 (3)
HIV-positive 1 (3)
 
Table 2. Patient treatment
Modality N (%)
Chemoradiation 26 (84)
Abdominoperineal resection 2 (6)
None 3 (10)
Stoma prior to chemoradiation 7 (30)
Table 3. Treatment toxicity
Toxicity N (%)
Acute
Radiation dermatitis 7 (27)
Thrombocytopenia 1 (3)
Neutropenia 1 (3)
Mucositis 1 (3)
Late
Anal stenosis 1 (3)
Pain 1 (3)
Table 4. Treatment outcome
Parameter N (%)
Initial complete response 21 (80)
No response 4 (15)
Lost to follow-up 1 (3)
Local relapse 3 (11)
Local and distant relapse 2 (7)
Distant relapse 2 (7)
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The purpose of this audit was to review the patient characteristics 
and outcome of treatment of anal canal carcinoma at GSH over a 
4-year period. We noted that there were more males than females. 
In general there is a slight female predominance for this disease.11 
The reported median age at diagnosis in the USA is 58 years.11 Our 
median age was 56 years. In South Africa one would expect a high 
incidence of patients with HIV infection. Only 1 patient was HIV 
positive although the status of 9 patients was not known. The rate 
of metastasis at presentation is low and occurred in only 1 patient, 
which is consistent with the low rate of 5 - 10% of patients reported 
elsewhere. Advanced disease (T3, T4) at presentation was present in 
67%, which is higher than in the USA where 30% of patients present 
with T3 or T4 tumours.11 Inguinal nodes were present in 38%. This is 
also much higher than the 20 - 25% of patients who presented with 
involved nodes reported from the USA.11
Chemoradiation was administered in 93% of patients. Grade 
2 - 3 skin and haematological toxicity requiring a break in 
treatment occurred in 38% of patients. An initial complete response 
to treatment was observed in 80% of patients. However, 27% 
subsequently relapsed, the majority experiencing local relapse.
We compared the outcome of our patients treated with 
chemoradiation with that reported in the literature. The United 
Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) 
and the European Organisation for Research and Treatment of Cancer 
(EORTC) used a similar regimen of mitomycin C, 5FU and 45.00 - 
50.00 Gy split-course radiation in the chemotherapy plus radiation 
arms.3,4 The local control rate at 5 years for this regimen in the EORTC 
trial was 69% while the local failure-free rate for the UKCCCR trial 
at 5 years was 32%. Our local control rate at 5 years was 60.7%. The 
colostomy-free survival at 5 years in the UKCCCR trial was 47%. Our 
colostomy-free survival was 59.2%. Overall survival on these trials in 
the chemotherapy arms was 58% at 5 years. Our overall survival was 
65.6% at 5 years. Our results are therefore comparable.
Subsequent trials have reported higher colostomy-free and overall 
survival figures. A recent phase III trial (ACT II), which prescribed 
radiation with no planned treatment gap and compared cisplatin 
with 5FU, as well as the role of maintenance chemotherapy, reported 
a 4 - 5% colostomy rate and over 80% overall survival at 3 years.8 
Locoregional control and overall survival are significantly affected 
by T and N stage.12,13 In the ACT II trial 44% of patients had T3, T4 
disease and 62% had negative nodes. In our patients 65% had T3 
and T4 disease and 38% had positive nodes. Although a different 
treatment regimen was used in ACT II, the local control and survival 
rates of our patients are probably related to advanced disease at 
presentation.
The major advantage of treatment with chemoradiation as opposed 
to surgery is organ preservation. Therefore colostomy-free survival 
is an important endpoint. In general the reason for performing a 
colostomy is APR for persistent disease or recurrence following 
treatment. However 23% of our patients required colostomies for 
faecal incontinence or obstruction prior to chemoradiation. Only 1 
patient had an attempt at reconstruction but subsequently developed 
faecal incontinence and required replacement of the colostomy. It 
was not possible to reverse the colostomies in the remaining patients 
because of loss of sphincter function. Only 3 patients (11%) required 
an APR for persistent disease or recurrence. Therefore the major 
contribution to our colostomy rate was locally advanced disease at 
presentation.
Our radiation techniques were simple with two-dimensional 
(2D) planning and treatment with 60-Cobalt. 5FU and mitomycin 
C chemotherapy agents are readily available and affordable. Our 
results, even for patients with locally advanced disease, were 
comparable to the UKCCCR and EORTC trials. Therefore curative 
treatment of carcinoma of the anal canal is possible with limited 
resources.
There is evidence that 3D conformal radiation treatment (3DCRT) 
using a high-energy linear accelerator is associated with less skin 
toxicity.14 This enables patients to complete treatment without breaks, 
which may improve local control.15,16 We have changed our treatment 
protocol to a continuous regimen of 50.00 Gy in 2.00 Gy fractions 
using 3D conformal radiotherapy where possible.
On review of the presenting history of many of our patients, we 
established that there had been several consultations with primary 
care physicians prior to referral and there was often a delay in 
diagnosis. It was also noted that some patients had been reluctant to 
seek medical attention in spite of having significant symptoms.
Conclusions
Squamous carcinoma of the anal canal is a disease which can be cured 
with radiation and chemotherapy while maintaining bowel function. 
The outcome however is related to disease stage at presentation. The 
patients in this study presented with advanced disease. The local 
control and overall survival rates at 5 years of 60.7% and 65.6% 
respectively compare favourably with trials using a similar treatment 
regimen. Cure can be achieved with widely available radiation 
techniques and chemotherapy agents. Early detection of this disease 
will improve the outcome for these patients.
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